摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1-hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester | 1289647-76-2

中文名称
——
中文别名
——
英文名称
2-(1-hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester
英文别名
2-(1-Hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester;methyl 2-(1-hydroxynaphthalen-2-yl)-1,3-benzoxazole-4-carboxylate
2-(1-hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester化学式
CAS
1289647-76-2
化学式
C19H13NO4
mdl
——
分子量
319.317
InChiKey
ZEFVLFGUGWOWKN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    72.6
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    2-(1-hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester 、 sodium hydroxide 作用下, 以 甲醇 为溶剂, 生成 2-(1-hydroxynaphthalen-2-yl)benzoxazole-4-carboxylic acid
    参考文献:
    名称:
    苯并咪唑和苯并恶唑锌螯合剂作为金属-β-内酰胺酶 NDM-1 的抑制剂
    摘要:
    细菌表达β-内酰胺酶,可水解β-内酰胺抗生素,导致抗菌药物耐药性的威胁日益严重。金属-β-内酰胺酶,例如 NDM-1,在其活性位点使用催化锌离子,并水解几乎所有临床上可用的 β-内酰胺抗生素。迫切需要金属-β-内酰胺酶抑制剂来克服这种耐药机制。锌结合化合物是抑制剂开发的有前景的先导化合物,因为许多 NDM-1 抑制剂含有锌结合药效团。在这里,我们评估了 13 种含有苯并咪唑和苯并恶唑支架的螯合剂作为 NDM-1 抑制剂。其中六种化合物显示出有效的抑制活性,IC 50值低至 0.38 μM,并且几种化合物恢复了表达 NDM-1 的大肠杆菌对美罗培南的敏感性。光谱和对接研究表明三元复合物的形成是抑制机制,使得这些化合物有望作为 NDM-1 抑制剂进行开发。
    DOI:
    10.1002/cmdc.202000607
  • 作为产物:
    描述:
    1-羟基-2-萘甲酸 在 palladium 10% on activated carbon 、 氢气4-甲基苯磺酸吡啶potassium carbonate 、 sodium hydroxide 作用下, 以 四氢呋喃乙酸乙酯N,N-二甲基甲酰胺间二甲苯 为溶剂, 20.0 ℃ 、206.85 kPa 条件下, 反应 42.0h, 生成 2-(1-hydroxy-naphthalen-2-yl)benzoxazole-4-carboxylic acid methyl ester
    参考文献:
    名称:
    UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication
    摘要:
    The bacterial natural product UK-1 and several structural analogs inhibit replication of the hepatitis C virus in the replicon assay, with IC50 values as low as 0.50 mu M. The NS3 helicase has been identified as a possible target of inhibition for several of these compounds, while the remaining inhibitors act via an undetermined mechanism. Gel shift assays suggest that helicase inhibition is a direct result of inhibitor-enzyme binding as opposed to direct RNA binding, and the ATPase activity of NS3 is not affected. The syntheses and biological results are presented herein. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.12.012
点击查看最新优质反应信息

文献信息

  • Heterocyclic Benzoxazole Compositions as Inhibitors of Hepatitis C Virus
    申请人:Smith Paul
    公开号:US20120208856A1
    公开(公告)日:2012-08-16
    This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.
    本发明涉及苯并噁唑化合物、递送它们的组合物和装置、制造它们的过程,以及在治疗丙型肝炎病毒中使用它们的方法。
  • Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
    申请人:Smith Paul
    公开号:US08822515B2
    公开(公告)日:2014-09-02
    This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.
    这项发明涉及苯并噁唑化合物、递送它们的组合物和装置、制造它们的过程以及在治疗丙型肝炎病毒中使用它们的方法。
  • US8822515B2
    申请人:——
    公开号:US8822515B2
    公开(公告)日:2014-09-02
  • [EN] HETEROCYCLIC BENZOXAZOLE COMPOSITIONS AS INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] COMPOSITIONS HÉTÉROCYCLIQUES DE BENZOXAZOLE À TITRE D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
    申请人:UNIV MARYLAND
    公开号:WO2011047390A2
    公开(公告)日:2011-04-21
    This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus.
  • UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication
    作者:Dawn N. Ward、Daniel C. Talley、Mrinalini Tavag、Samrawit Menji、Paul Schaughency、Andrea Baier、Paul J. Smith
    DOI:10.1016/j.bmcl.2013.12.012
    日期:2014.1
    The bacterial natural product UK-1 and several structural analogs inhibit replication of the hepatitis C virus in the replicon assay, with IC50 values as low as 0.50 mu M. The NS3 helicase has been identified as a possible target of inhibition for several of these compounds, while the remaining inhibitors act via an undetermined mechanism. Gel shift assays suggest that helicase inhibition is a direct result of inhibitor-enzyme binding as opposed to direct RNA binding, and the ATPase activity of NS3 is not affected. The syntheses and biological results are presented herein. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多